Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy

BACKGROUND: Platinum-based therapy, combined or not with immune checkpoint inhibitors, represents a front-line choice for patients with non-small-cell lung cancer (NSCLC). Despite the improved outcomes in the last years for this malignancy, only a sub-group of patients have long-term benefit. Excisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganzinelli, M., Linardou, H., Alvisi, M.F., Caiola, E., Lo Russo, G., Cecere, F.L., Bettini, A.C., Psyrri, A., Milella, M., Rulli, E., Fabbri, A., De Maglie, M., Romanelli, P., Murray, S., Broggini, M., Marabese, M., Garassino, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809372/
https://www.ncbi.nlm.nih.gov/pubmed/33422766
http://dx.doi.org/10.1016/j.esmoop.2020.100034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809372/
https://www.ncbi.nlm.nih.gov/pubmed/33422766
http://dx.doi.org/10.1016/j.esmoop.2020.100034

Ejemplares similares